Remove Biobanking Remove Clinical Trials Remove Life Science Remove Research
article thumbnail

Supercharging AI-drug discovery with strategic multiomic biobanks 

Drug Discovery World

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. Research that once took months to complete – requiring synthesizing and testing compounds – can now be done in days and even hours using AI. But the utility of biobanks varies.

article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. The life sciences sector has traditionally outperformed others when it comes to attracting women to its workforce. Dr Loubna Bouarfa, Founder and CEO, OKRA.ai

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Manchester to get £60m development to enhance lab space

Drug Discovery World

million development in Manchester intended to enhance the city’s Oxford Road Corridor knowledge quarter as a hub for life sciences and technology innovation. Greenheys at Manchester Science Park is scheduled for completion in Summer 2026 and will span 131,000 sq ft across six floors. Work has started on a £60 ($75.1)

article thumbnail

The post-Covid New Normal: a golden opportunity for the NHS?

pharmaphorum

I recently had the pleasure of attending the PING Conference 2022 , which had the tagline of ‘The Golden Age for Life Sciences Innovation’. Aspirations for the UK in life sciences. Faster access for patients for interventions. Data on all aspects, including stratification of patient types.

article thumbnail

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

The Pharma Data

Bayer is progressing novel research around its prostate cancer treatment darolutamide. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients. Data from all three areas of scientific focus will be showcased during this year’s meeting.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

Data generated through high-throughput omics approaches paired with clinical patient records can give rise to remarkably robust datasets to inform and guide disease insights and development of targeted therapeutics. Generation of strong research dataset cohorts must begin with high-quality clinical samples.

article thumbnail

Digitalized HBSM: The Greatest Advantages

Cloudbyz

Advantages gained from digitalization are certainly not limited to Human Biosample Management (HBSM) or any other applied aspects of the Life Sciences. Is it now stored in a biobank? If a sample source has been verified you can make it available for research associates (RAs) to start testing right away. Timely eConsent.